Publications

Lists of publications from Dr. Sikora and the Sikora Laboratory are maintained below, and also at the below sites. Contact us for reprint requests, reagent/protocol information, or other inquiries.

2021

WNT4; women's health
Pitzer LM, Moroney MR, Nokoff NJ, Sikora MJ. WNT4 Balances Development vs Disease in Gynecologic Tissues and Women's Health. Endocrinology. 2021 Jul 1;162(7):bqab093. doi: 10.1210/endocr/bqab093. PMID: 33963381.

Estrogen receptor function; Invasive lobular carcinoma biology
[Sottnik JL, Bordeaux EK]*, Mehrotra S, Ferrara SE, Goodspeed AE, Costello JC, Sikora MJ. Mediator of DNA damage checkpoint 1 (MDC1) is a novel estrogen receptor co-regulator in invasive lobular carcinoma of the breast. Mol Cancer Res. 2021 May 4. doi: 10.1158/1541-7786.MCR-21-0025. PMID: 33947745.
*, Authors contributed equally.

Career development; NR IMPACT
Sikora MJ, Riggins RB, Madak-Erdogan Z. Making an IMPACT on career development for early- and mid-career faculty. Endocrinology. 2021 Jan 7:bqaa247. doi: 10.1210/endocr/bqaa247. Epub ahead of print. PMID: 33411889.

2019

WNT4
Rao DM, Shackleford MT, Bordeaux EK, Sottnik JL, Ferguson RL, Yamamoto TM, Wellberg EA, Bitler BG, Sikora MJ. Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine O-acyltransferase or Wnt secretion. J Biol Chem. 2019 Dec 27;294(52):19950-19966. doi: 10.1074/jbc.RA119.009615. Epub 2019 Nov 18. PMID: 31740580; PMCID: PMC6937561.

Invasive lobular carcinoma biology; Anti-estrogen resistance in breast cancer
Levine KM, Priedigkeit N, Basudan A, Tasdemir N, Sikora MJ, Sokol ES, Hartmaier RJ, Ding K, Ahmad NZ, Watters RJ, Weiss KR, Blohmer JU, Denkert C, Machleidt A, Karsten MM, Boisen MM, Elishaev E, Lucas PC, Lee AV, Oesterreich S. FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. NPJ Breast Cancer. 2019 Jun 27;5:19. doi: 10.1038/s41523-019-0114-x. PMID: 31263748; PMCID: PMC6597581.

Invasive lobular carcinoma biology
Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Levine KM, Jankowitz RC, McAuliffe PF, Dabbs D, Haupt S, Haupt Y, Lucas PC, Lee AV, Oesterreich S, Atkinson JM. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. Cancer Lett. 2019 Oct 1;461:21-30. doi: 10.1016/j.canlet.2019.06.011. Epub 2019 Jun 20. PMID: 31229512; PMCID: PMC6682463.

WNT4; Ovarian cancer biology
Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Mol Carcinog. 2019 Oct;58(10):1770-1782. doi: 10.1002/mc.23064. Epub 2019 Jun 10. PMID: 31219654; PMCID: PMC7537108.

Estrogen receptor function; Invasive lobular carcinoma biology
Bossart EA, Tasdemir N, Sikora MJ, Bahreini A, Levine KM, Chen J, Basudan A, Jacobsen BM, Burns TF, Oesterreich S. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Res Treat. 2019 Jun;175(2):327-337. doi: 10.1007/s10549-019-05161-8. Epub 2019 Feb 23. PMID: 30798422; PMCID: PMC6625318.


2017

Estrogen receptor function; Anti-estrogen resistance in breast cancer; Invasive lobular carcinoma biology
Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017 Nov 30;8(1):1865. PubMed PMID: 29192207.

Pharmacogenomics
Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov;166(1):277-287. doi: 10.1007/s10549-017-4400-8. Epub 2017 Jul 20. PubMed PMID: 28730340.

Estrogen receptor function (Commentary)
Hsu JY, Sikora MJ. CRISPR Fish Reel in Novel Roles for Estrogen Receptors in Reproduction. Endocrinology. 2017 Jul 1;158(7):2082-2083. doi: 10.1210/en.2017-00417. PubMed PMID: 28881866

Estrogen receptor function; Ovarian cancer biology
Andersen CL, Sikora MJ, Boisen MM, Ma T, Christie A, Tseng G, Park YS, Luthra S, Chandran U, Haluska P, Mantia-Smaldone G, Odunsi K, McLean K, Lee AV, Elishaev E, Edwards RP, Oesterreich S. Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens. Clin Cancer Res. 2017 Jul 15;23(14):3802-3812. doi: 10.1158/1078-0432.CCR-16-1501. Epub 2017 Jan 10. PubMed PMID: 28073843.

2016

Estrogen receptor function (Review)
Sikora MJ. Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy. Endocrinology. 2016 Dec;157(12):4553-4560. PMID: 27835038; PMCID: PMC5133350.

WNT4; Invasive lobular carcinoma biology; Estrogen receptor function
Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, Alexander CM, Oesterreich S. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res. 2016 Sep 20;18(1):92. doi: 10.1186/s13058-016-0748-7. PMID: 27650553; PMCID: PMC5028957.

Methods; Estrogen receptor function
Sikora MJ, Johnson MD, Lee AV, Oesterreich S. Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability. Endocrinology. 2016 Oct;157(10):3760-3766. PMID: 27459541; PMCID: PMC5045515.

Invasive lobular carcinoma biology
Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin AA, Welm A, Oesterreich S, Sikora MJ, Brown RE, Mills GB. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. Clin Cancer Res. 2016 Oct 15;22(20):5068-5078. PMID: 27172895; PMCID: PMC5103285.

Anti-estrogen resistance in breast cancer; Estrogen receptor function
Capper CP, Larios JM, Sikora MJ, Johnson MD, Rae JM. The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. Breast Cancer Res Treat. 2016 May;157(1):23-30. doi: 10.1007/s10549-016-3774-3. PMID: 27083183.

Ovarian cancer biology
Delgado E, Boisen MM, Laskey R, Chen R, Song C, Sallit J, Yochum ZA, Andersen CL, Sikora MJ, Wagner J, Safe S, Elishaev E, Lee A, Edwards RP, Haluska P, Tseng G, Schurdak M, Oesterreich S. High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol. 2016 May;141(2):348-56. doi: 10.1016/j.ygyno.2016.02.030. PMID: 26946093; PMCID: PMC5154956.